2. Malmstrom H, Walldius G, Grill V, et al. Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies--cross-sectional and longitudinal experience from the AMORIS cohort. PLoS One. 2014; 9:e111463.
3. Lab Tests Online. Fructosamine testing. Available at: http://labtestsonline.org.uk/understandi... Accessed on: 23/05/2015.
4. Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care. 2010; 33:1895-1902.
5. Salti I, Benard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004; 27:2306-2311.
6. EMA. Victoza(R) EU Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... Last accessed 01.05.2015.
7. Internal Calculations based on IMS Midas Quantum data. March 2015.
8. FDA. Victoza(R) US prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda... Last accessed 01.05.2015.
Further Information
Media:
Katrine Sperling +45-4442-6718 krsp@novonordisk.com
Michael Bachner (US) +1-609-664-7308 mzyb@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45-3079-4303 krop@novonordisk.com
Melanie Raouzeos +45-3075-3479 mrz@novonordisk.com
Daniel Bohsen +45-3079-6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1-609-235-8567 fdni@novonordisk.com
